| Objective:Patients with esophageal squamous cell carcinoma used iTRAQ technology to screen for proteins that showed differences in serum in terms of efficacy and prognosis after radiotherapy and chemotherapy.Methods: 1.91 cases of patients with locally advanced and advanced esophageal squamous cell carcinoma were included,and appropriate radiotherapy and chemotherapy were selected according to the comprehensive situation,and the efficacy evaluation of patients was dynamically followed up;at the same time,they were collected before and after the course of treatment.Peripheral blood.2.Collect the peripheral blood of patients with esophageal squamous cell carcinoma before and after the course of treatment,apply iTRAQ technology to the identification and quantification of the protein in the blood,and analyze the biologically meaningful behavior of the protein at the same time.Considering the importance of the protein of interest and patients with esophageal squamous cell carcinoma in terms of treatment efficacy and prognosis,the purpose of testing differential proteins is achieved.Results: 1.Effective results in recent response therapy: group with good performance in treatment: disease control rate(CR + PR + SD,DCR)patients with esophageal cancer accounted for 56.04%(51/91)of the total The proportion of patients with poor performance(PD)accounted for 43.96%(40/91)of all patients,and the results of long-term response therapy were effective: 23.07% of patients with total survival(OS)≥ 3 years after treatment(21/91 cases),patients with total survival(OS)<3 years after treatment accounted for 76.93%(70/91 cases).2.Screening and comparison between patients with esophageal squamous cell carcinoma before receiving radiochemotherapy and healthy normal control group: a total of 54 differential proteins were found with different expressions,and 29 and 25 proteins were up-regulated and down-regulated respectively.Pcs.3.Plasma serine protease inhibitor(SERPINA5)also appeared in theesophageal squamous cell carcinoma patients with overall survival(OS)≥ 3 years group and after treatment overall survival(OS)<3 years group,and simultaneously increased up.Conclusion:Serum differential protease inhibitor(SERPINA5)is a potential predictor of efficacy and prognosis after radiotherapy and chemotherapy for esophageal squamous cell carcinoma. |
PDF Full Text Request